Collectively, these results indicated that DRD5 and TFAP2A, as potential targets of CPAP for OSA treatment, were also key genes in the pathogenesis of OSA, and had good diagnostic value. This evidence concerns the gene DRD5 and obstructive sleep apnea syndrome.